Dirk J. de Jong

7.9k citations

119 papers · 4.4k indexed · h-index 39

Impact in

Genetics top 0.5%
- Inflammatory Bowel Disease
Immunology top 2%
- Immune Response and Inflammation

Papers in

Genetics 74
- Inflammatory Bowel Disease 74
Immunology 31
- Immune Response and Inflammation 10
- Immunodeficiency and Autoimmune Disorders 10

Co-authors: Mihai G. Netea Joost P.H. Drenth Bart Jan Kullberg Gerben Ferwerda Stephen E. Girardin Bas Oldenburg C. Janneke van der Woude Pieter Stokkers
Journals: Gastroenterology (15 papers)Inflammatory Bowel Diseases (14 papers)Journal of Crohn s and Colitis (8 papers)Gut (6 papers)Alimentary Pharmacology & Therapeutics (5 papers)
Partner nations: Netherlands United States Germany

In The Last Decade

Dirk J. de Jong

113 papers receiving 4.3k citations

Peers

Countries citing papers authored by Dirk J. de Jong

Since Specialization

Citations

This map shows the geographic impact of Dirk J. de Jong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk J. de Jong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk J. de Jong more than expected).

Fields of papers citing papers by Dirk J. de Jong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk J. de Jong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk J. de Jong. The network helps show where Dirk J. de Jong may publish in the future.

Co-authors

The 25 scholars most cited alongside Dirk J. de Jong, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Dirk J. de Jong Line = papers co-authored together Dirk J. de Jong links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Feasibility of Reduced Clinical Monitoring in Patients with Inflammatory Bowel Disease Treated with Thiopurine Therapy Digestive Diseases and Sciences ·Fenna M. Jansen, Lisa Smits, Pepijn W. A. Thomas, Dirk J. de Jong, Joany E. Kreijne, Willemijn A. van Dop, Nathan den Broeder, Frank Hoentjen	2023	0
2	Lengthening adalimumab dosing interval in quiescent Crohn’s disease patients: protocol for the pragmatic randomised non-inferiority LADI study BMJ Open ·Lisa Smits, R Pauwels, Wietske Kievit, Dirk J. de Jong, Annemarie C. de Vries, Frank Hoentjen, C. Janneke van der Woude, (unknown)	2020	2
3	The Impact of Ethnicity and Country of Birth on Inflammatory Bowel Disease Phenotype: a Prospective Cohort Study Journal of Crohn s and Colitis ·Lieke M. Spekhorst, Mirjam Severs, Nanne K.H. de Boer, Eleonora A. Festen, Herma H. Fidder, Frank Hoentjen, Floris Imhann, Dirk J. de Jong, Andrea E. van der Meulen‐de Jong, Marie J. Pierik, C. Janneke van der Woude, Gerard Dijkstra, Cyriel Y. Ponsioen, Mark Löwenberg, Bas Oldenburg, Rinse K. Weersma	2017	7
4	Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease Digestive Diseases and Sciences ·Lisa Smits, Anna Grelack, Lauranne Derikx, Dirk J. de Jong, Aura A. J. van Esch, Ronald S. Boshuizen, Joost P.H. Drenth, Frank Hoentjen	2017	61
5	Allopurinol and 5-aminosalicylic acid influence thiopurine-induced hepatotoxicity in vitro Cell Biology and Toxicology ·Mark M. T. J. Broekman, Hennie M.J. Roelofs, Dennis R. Wong, Mariska Kerstholt, Alex Leijten, Frank Hoentjen, Wilbert H.M. Peters, Geert Wanten, Dirk J. de Jong	2015	13
6	Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease Gut ·Bindia Jharap, Nanne K.H. de Boer, Pieter Stokkers, Daniël W. Hommes, Bas Oldenburg, Gerard Dijkstra, C. Janneke van der Woude, Dirk J. de Jong, Chris J. Mulder, Ruurd M. van Elburg, Adriaan A. van Bodegraven, (unknown)	2013	102
7	Effect of childbirth on the course of Crohn's disease; results from a retrospective cohort study in the Netherlands BMC Gastroenterology ·Marieke Smink, Frederik K. Lotgering, Lisette Albers, Dirk J. de Jong	2011	30
8	Risk of malignant lymphoma in patients with inflammatory bowel diseases: A Dutch nationwide study Inflammatory Bowel Diseases ·Anne Christine W. Vos, Noor Bakkal, Robert C. Minnee, M.K. Casparie, Dirk J. de Jong, Gerard Dijkstra, Pieter Stokkers, Ad A. van Bodegraven, (unknown), C. Janneke van der Woude, Bas Oldenburg, Daniël W. Hommes	2010	74
9	Richtlijn ‘Diagnostiek en behandeling van inflammatoire darmziekten bij volwassenen’. I. Diagnostiek en behandeling Nederlandsch tijdschrift voor geneeskunde/Nederlands tijdschrift voor geneeskunde/NTvG-databank ·Ad A. van Bodegraven, J J van Everdingen, Gerard Dijkstra, Dirk J. de Jong, Bas Oldenburg, DW Hommes	2010	6
10	Recognition ofBorrelia burgdorferiby NOD2 Is Central for the Induction of an Inflammatory Reaction The Journal of Infectious Diseases ·Marije Oosting, Anneleen Berende, Patrick Sturm, Hadewych J. M. ter Hofstede, Dirk J. de Jong, Thirumala‐Devi Kanneganti, Jos W.M. van der Meer, Bart Jan Kullberg, Mihai G. Netea, Leo A. B. Joosten	2010	59
11	The Functional −765G→C Polymorphism of the COX-2 Gene May Reduce the Risk of Developing Crohn's Disease PLoS ONE ·Hilbert S. de Vries, René H. M. te Morsche, Martijn G.H. van Oijen, Irıs D. Nagtegaal, Wilbert H.M. Peters, Dirk J. de Jong	2010	14
12	Microalbuminuria Is Not a Valuable Marker for Relapse in Crohn’s Disease Digestion ·Carmen S. Horjus, Martijn G.H. van Oijen, Abby Davids, A.H.J. Naber, Dirk J. de Jong	2010	0
13	More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis Inflammatory Bowel Diseases ·Marian M. Claessen, Maurice Lutgens, Henk R. van Buuren, Bas Oldenburg, Pieter Stokkers, C. Janneke van der Woude, Daniël W. Hommes, Dirk J. de Jong, Geke Dijkstra, Ad A. van Bodegraven, Peter D. Siersema, Frank P. Vleggaar	2009	94
14	Genetic Analysis in A Dutch Study Sample Identifies More Ulcerative Colitis Susceptibility Loci and Shows Their Additive Role in Disease Risk The American Journal of Gastroenterology ·Eleonora A. Festen, Pieter Stokkers, Cleo C. van Diemen, Adriaan A. van Bodegraven, Marieke H. Boezen, Bart J. A. Crusius, Daniël W. Hommes, C. Janneke van der Woude, Tobias Balschun, Hein W. Verspaget, Stephan J. Schreiber, Dirk J. de Jong, Andre Franke, Gerard Dijkstra, Cisca Wijmenga, Rinse K. Weersma	2009	37
15	Extended Thiopurine Metabolite Assessment During 6‐Thioguanine Therapy for Immunomodulation in Crohn's Disease The Journal of Clinical Pharmacology ·Nanne K.H. de Boer, Luc J. J. Derijks, Jenneke J. Keizer-Garritsen, L. H. J. Lambooy, W. Ruitenbeek, P. M. Hooymans, Adriaan A. van Bodegraven, Dirk J. de Jong	2007	13
16	CARD15 in inflammatory bowel disease and Crohn's disease phenotypes: An association study and pooled analysis Digestive and Liver Disease ·Liekele E. Oostenbrug, Ilja M. Nolte, Elvira Oosterom, Gerrit van der Steege, G.J. te Meerman, Hendrik M. van Dullemen, Joost P.H. Drenth, Dirk J. de Jong, K Linde, P. L. M. Jansen, Jan H. Kleibeuker	2006	24
17	The Frameshift Mutation in Nod2 Results in Unresponsiveness Not Only to Nod2- but Also Nod1-activating Peptidoglycan Agonists Journal of Biological Chemistry ·Mihai G. Netea, Gerben Ferwerda, Dirk J. de Jong, Catherine Werts, Ivo G. Boneca, Muguette Jéhanno, J.W.M. van der Meer, Dominique Mengin‐Lecreulx, Philippe Sansonetti, Dana J. Philpott, Sébastien Dharancy, Stephen E. Girardin	2005	67
18	NOD2 mediates anti‐inflammatory signals induced by TLR2 ligands: implications for Crohn's disease European Journal of Immunology ·Mihai G. Netea, Bart Jan Kullberg, Dirk J. de Jong, Barbara Franke, Tom Sprong, Ton Naber, Joost P.H. Drenth, Jos W.M. van der Meer	2004	177
19	Safety of thiopurines in the treatment of inflammatory bowel disease Scandinavian Journal of Gastroenterology ·Dirk J. de Jong, Luc J. J. Derijks, A.H.J. Naber, P. M. Hooymans, C. J. J. Mulder	2003	45
20	Addition of simethicone improves small bowel capsule endoscopy visualisation quality. Sight & sound/Sight and sound ·Krijbolder, Karina V. Grooteman, S.K. Bogers, Dirk J. de Jong	1993	8

About Dirk J. de Jong

Dirk J. de Jong is a scholar working on Genetics, Immunology, Epidemiology, Hepatology and Gastroenterology, having authored 119 papers that have together received 4.4k indexed citations. Recurring topics across this work include Inflammatory Bowel Disease (74 papers), Microscopic Colitis (36 papers), Acute Lymphoblastic Leukemia research (21 papers), Helicobacter pylori-related gastroenterology studies (13 papers), Immune Response and Inflammation (10 papers), Immunodeficiency and Autoimmune Disorders (10 papers), Pregnancy and Medication Impact (9 papers) and Eosinophilic Esophagitis (9 papers). The work is most often cited by research in Genetics (2.0k citations), Immunology (1.5k citations), Epidemiology (1.6k citations), Hepatology (235 citations) and Gastroenterology (142 citations). Dirk J. de Jong has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Mihai G. Netea, Joost P.H. Drenth, Bart Jan Kullberg, Gerben Ferwerda, Stephen E. Girardin, Bas Oldenburg, C. Janneke van der Woude, Pieter Stokkers, Gerard Dijkstra and J.W.M. van der Meer. Their work appears in journals such as Gastroenterology, Inflammatory Bowel Diseases, Journal of Crohn s and Colitis, Gut and Alimentary Pharmacology & Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact